Pfizer Opens New Development Centre
BRUSSELS, Belgium (Business Wire EON) April 18, 2008 --
A new development centre for veterinary vaccines which will accelerate
the development of new animal health products has been opened by Pfizer
as part of its annual $300 million (US dollar) commitment to research
and development.
The new centre is located on the Louvain-la-Neuve scientific plant near
Brussels.
"This is an historic occasion for Pfizer Animal Health,”
said Juan Ramon Alaix, president of Pfizer Animal Health, "because it is
our first pilot plant in Europe for developing animal vaccines. It also
demonstrates the strength and value of our continuing partnership with
our PGM colleagues.”
The new facility houses the development operations for products and
processes in the area of formulation, filling and lyophilisation of
products. The company’s decision to establish
its development centre on the same site at which new products will be
manufactured is a strategic one. The decision makes it possible for the
production site to become more involved in developing new products.
The plant is at the cutting edge of biotechnologies and aseptic
operations and employs over 200 people. New on the site is an integrated
line for filling vaccines in plastic vials which is dedicated to
manufacturing vaccines for pigs which includes the product, Improvac.
This is a vaccine to combat boar taint in pigs and is a viable
alternative to physical castration. The vaccine has a huge potential as
it combines the search for economic advantages with the welfare of
animals.
More than 400 finished products from the site are distributed throughout
Europe, the US and Brazil and represents an annual volume of 125 million
doses with a turnover of approximately $150 million dollars.
MULTIMEDIA GALLERY http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5662069
Post Comment:
Trackback URL: http://eon.businesswire.com/pingpr.php/RW1wdC1NYWduLVNxdWEtSGFsZi1GYWx1LVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
